Core Insights - Allarity Therapeutics presented new clinical data for stenoparib, a dual PARP/Wnt pathway inhibitor, at the SGO 2025 Annual Meeting, highlighting its potential in treating advanced ovarian cancer [1][2] Group 1: Clinical Trial Findings - The Phase 2 trial of stenoparib involved patients with advanced, recurrent ovarian cancer who had undergone three or more lines of therapy, with a focus on those with platinum-resistant disease [3][4] - Among the 15 enrolled patients, 14 were platinum-resistant, and one was primary platinum-refractory, with limited effective treatment options available [3] - Notably, one patient achieved a confirmed complete response lasting over 10 months, and two patients remain on therapy for more than 17 months [3][4] Group 2: Unique Mechanism and Patient Benefit - Stenoparib demonstrated clinical benefits in patients without BRCA mutations, indicating its unique dual action in inhibiting both PARP and the Wnt pathway [4][8] - The study is the first to dose stenoparib twice daily, optimizing the inhibition of PARP and Tankyrase, and showing potential durable clinical benefits in heavily pre-treated patients [8][9] Group 3: Future Directions and Company Strategy - The results from the exploratory Phase 2 study are foundational for Allarity, supporting the development of a new protocol to evaluate stenoparib in platinum-resistant patients [9][12] - Allarity is committed to addressing unmet medical needs in cancer treatment, focusing on personalized therapies and the development of companion diagnostics for stenoparib [11][12]
Allarity Therapeutics Announces Presentation of Phase 2 Clinical Data from Ongoing Trial in Advanced Ovarian Cancer Patients at the 2025 Annual Meeting for the Society of Gynecologic Oncology